Literature DB >> 36085186

[History of the biologics treatment of axial spondylarthritis-Part 2].

Joachim Sieper1, Jürgen Braun2.   

Abstract

Entities:  

Year:  2022        PMID： 36085186     DOI： 10.1007/s00393-022-01264-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.530


× No keyword cloud information.
  46 in total

Review 1.  Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference?

Authors:  Jurgen Braun; Xenofon Baraliakos; Uta Kiltz; Frank Heldmann; Joachim Sieper
Journal:  J Rheumatol       Date:  2014-11-15       Impact factor: 4.666

2.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

3.  Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).

Authors:  Xenofon Baraliakos; Mikkel Østergaard; Lianne S Gensler; Denis Poddubnyy; Eun Young Lee; Uta Kiltz; Ruvie Martin; Hiroshi Sawata; Aimee Readie; Brian Porter
Journal:  Clin Drug Investig       Date:  2020-03       Impact factor: 2.859

4.  Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

Authors:  Jan Brandt; Hildrun Haibel; Jaqueline Reddig; Joachim Sieper; Jürgen Braun
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

5.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

6.  Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial.

Authors:  J Braun; J Zochling; X Baraliakos; R Alten; G Burmester; K Grasedyck; J Brandt; H Haibel; M Hammer; A Krause; F Mielke; H-P Tony; W Ebner; B Gömör; J Hermann; H Zeidler; E Beck; M Baumgaertner; J Sieper
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

7.  Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.

Authors:  Henning Christian Brandt; Inge Spiller; In-Ho Song; Janis L Vahldiek; Martin Rudwaleit; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

8.  Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Authors:  Dominique Baeten; Mikkel Østergaard; James Cheng-Chung Wei; Joachim Sieper; Pentti Järvinen; Lai-Shan Tam; Carlo Salvarani; Tae-Hwan Kim; Alan Solinger; Yakov Datsenko; Chandrasena Pamulapati; Sudha Visvanathan; David B Hall; Stella Aslanyan; Paul Scholl; Steven J Padula
Journal:  Ann Rheum Dis       Date:  2018-06-26       Impact factor: 19.103

9.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Dominique Baeten; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper; Paul Emery; Désirée van der Heijde; Iain McInnes; Jacob M van Laar; Robert Landewé; Paul Wordsworth; Jürgen Wollenhaupt; Herbert Kellner; Jacqueline Paramarta; Jiawei Wei; Arndt Brachat; Stephan Bek; Didier Laurent; Yali Li; Ying A Wang; Arthur P Bertolino; Sandro Gsteiger; Andrew M Wright; Wolfgang Hueber
Journal:  Lancet       Date:  2013-09-13       Impact factor: 79.321

10.  Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.

Authors:  Atul Deodhar; Ricardo Blanco; Eva Dokoupilová; Stephen Hall; Hideto Kameda; Alan J Kivitz; Denis Poddubnyy; Marleen van de Sande; Anna S Wiksten; Brian O Porter; Hanno B Richards; Sibylle Haemmerle; Jürgen Braun
Journal:  Arthritis Rheumatol       Date:  2020-11-24       Impact factor: 15.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.